The E-cadherin (CDH1) -160 C/A polymorphism and prostate cancer risk: A meta-analysis

European Journal of Human Genetics

Volumn 17, Issue 2, 2009, Pages 244-249

  Qiu, Li Xin ^a,b   Li, Ru Tian ^b   Zhang, Jian Bing ^c   Zhong, Wen Zhao ^d   Bai, Jian Ling ^a   Liu, Bao Rui ^a,b   Zheng, Ming Hua ^e   Qian, Xiao Ping ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c NANTONG UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN;

AFRICAN AMERICAN; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HISPANIC; HOMOZYGOTE; HUMAN; MUTATIONAL ANALYSIS; PENETRANCE; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

CADHERINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 58349105348     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2008.157     Document Type: Article

References (32)

1. Siddiqui E, Mumtaz F, Gelister J: Understanding prostate cancer. J R Soc Health 2004; 124: 219-221.
2. Lichtenstein P, Holm NV, Verkasalo PK: Environmental and heritable factors in the causation of cancer. N Engl J Med 2000; 343: 78-85.
3. Gsur A, Feik E, Madersbacher S: Genetic polymorphisms and prostate cancer risk. World J Urol 2004; 21: 414-423.
4. Simard J, Dumont M, Labuda D et al: Prostate cancer susceptibility genes: Lessons learned and challenges posed. Endocr Relat Cancer 2003; 10: 225-259.
5. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 22: 1451-1455.
6. Pecina-Slaus N: Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003; 3: 17.
7. Berx G, Becker K, Hofler H, Roy F: Mutations in the human E-cadherin (CDH1) gene. Hum Mutat 1998; 12: 226-237.
8. Nakamura A, Shimazaki T, Kaneko K et al: Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region. Mutat Res 2002; 502: 19-24.
9. Li LC, Chui RM, Sasaki M et al: A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 2000; 60: 873-879.
10. Umbas R, Isaacs WB, Bringuier PP et al: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 3929-3938.
11. Dunsmuir WD, Gillett CE, Meyer LC: Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000; 86: 869-878.
12. Woolf B: On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
13. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J: A method for meta-analysis of molecular association studies. Stat Med 2005; 24: 1291-1306.
14. Cochran WG: The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
15. Petitti D: Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York: Oxford University Press, 1994.
16. Tobias A: Assessing the influence of a single study in the metaanalysis estimate. Stata Tech Bull 1999; 8: 15-17.
17. Egger M, Davey Smith G, Schneider M, Minder C: Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
18. Verhage BA, van Houwelingen K, Ruijter TE, Kiemeney LA, Schalken JA: Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer 2002; 100: 683-685.
19. Hajdinjak T, Toplak N: E-cadherin polymorphism -160 C/A and prostate cancer. Int J Cancer 2004; 109: 480-481.
20. Jonsson BA, Adami HO, Hagglund M et al: -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 2004; 109: 348-352.
21. Lindstrom S,Wiklund F, Jonsson BA et al: Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: Strong confirmation of functional promoter SNP. Hum Genet 2005; 118: 339-347.
22. Pookot D, Li LC, Tabatabai ZL et al: The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol 2006; 176: 793-796.
23. Bonilla C, Mason T, Long L et al: E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate 2006; 66: 546-556.
24. Tsukino H, Kuroda Y, Imai H et al: Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int 2004; 72: 203-207.
25. Kamoto T, Isogawa Y, Shimizu Y et al: Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population. Jpn J Clin Oncol 2005; 35: 158-161.
26. Goto T, Nakano M, Ito S et al: Significance of an E-cadherin gene promoter polymorphism for risk and disease severity of prostate cancer in a Japanese population. Urology 2007; 70: 127-130.
27. Tsukino H, Kuroda Y, Nakao H et al: E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett 2003; 195: 53-59.
28. Wu MS, Huang SP, Chang YT et al: Association of the -160 C/A a promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer 2002; 94: 1443-1449.
29. Hirschhorn JN, Lohmueller K, Byrne E: A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.
30. Wacholder S, Chanock S, Garcia-Closas M: Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-442.
31. Munafò MR, Flint J: Meta-analysis of genetic association studies. Trends Genet 2004; 20: 439-444.
32. Rodriguez C, Calle EE, Miracle-McMahill HL et al: Family history and risk of fatal prostate cancer. Epidemiology 1997; 8: 653-659.